<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.31579.009</object-id><label>Table 1.</label><caption><title>Adjusted Odds Ratios (aOR) for severe malaria by <italic>Sl2</italic> (recessive) and <italic>McC<sup>b</sup></italic> (additive) genotype in Kenya.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Clinical outcome</th><th valign="top"><italic>Sl2&#160;</italic>aORs (95% CI)*</th><th valign="top"><italic>P</italic> value</th><th valign="top"><italic>McC<sup>b</sup></italic> aORs (95% CI)</th><th valign="top"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top">All severe malaria<sup>&#8224;</sup> (n&#160;=&#160;1716)</td><td valign="top"><bold>0.78 (0.64&#8211;0.95)</bold></td><td valign="top"><bold>0.011</bold></td><td valign="top">1.10 (0.97&#8211;1.25)</td><td valign="top">0.108</td></tr><tr><td valign="top">CM<sup>&#167;</sup> (n&#160;=&#160;943)</td><td valign="top"><bold>0.67 (0.52&#8211;0.87)<sup>&#8225;</sup></bold></td><td valign="top"><bold>0.006</bold></td><td valign="top"><bold>1.19 (1.02&#8211;1.38)</bold></td><td valign="top"><bold>0.025</bold></td></tr><tr><td valign="top">Severe without CM (n&#160;=&#160;674)</td><td valign="top">1.00 (0.76&#8211;1.30)</td><td valign="top">0.994</td><td valign="top">0.98 (0.82&#8211;1.17)</td><td valign="top">0.811</td></tr><tr><td valign="top">Died (n&#160;=&#160;180)<sup>&#8224;</sup></td><td valign="top"><bold>0.50 (0.30&#8211;0.80)<sup>&#8225;</sup></bold></td><td valign="top"><bold>0.002</bold></td><td valign="top">1.31 (0.95&#8211;1.72)</td><td valign="top">0.086</td></tr><tr><td valign="top">Died with CM (n&#160;=&#160;131)</td><td valign="top"><bold>0.44 (0.23&#8211;0.78)<sup>&#8225;</sup></bold></td><td valign="top"><bold>0.007</bold></td><td valign="top">1.34 (0.94&#8211;1.88)</td><td valign="top">0.104</td></tr><tr><td valign="top">Died without CM (n&#160;=&#160;42)</td><td valign="top">0.73 (0.18&#8211;2.30)</td><td valign="top">0.636</td><td valign="top">1.00 (0.48&#8211;1.94)</td><td valign="top">0.940</td></tr><tr><td valign="top">SMA<sup>#</sup> (n&#160;=&#160;483)</td><td valign="top">0.76 (0.55&#8211;1.05)</td><td valign="top">0.099</td><td valign="top">0.96 (0.78&#8211;1.17)</td><td valign="top">0.688</td></tr><tr><td valign="top">SMA without CM (n&#160;=&#160;223)</td><td valign="top">0.82 (0.51&#8211;1.26)</td><td valign="top">0.366</td><td valign="top">0.91 (0.67&#8211;1.20)</td><td valign="top">0.553</td></tr><tr><td valign="top">Died with SMA<sup>&#182;</sup> (n&#160;=&#160;56)</td><td valign="top">0.65 (0.21&#8211;1.67)</td><td valign="top">0.374</td><td valign="top">1.35 (0.77&#8211;2.20)</td><td valign="top">0.229</td></tr><tr><td valign="top">RD** (n&#160;=&#160;522)</td><td valign="top">0.81 (0.59&#8211;1.10)</td><td valign="top">0.181</td><td valign="top">1.12 (0.92&#8211;1.35)</td><td valign="top">0.225</td></tr><tr><td valign="top">RD without CM (n&#160;=&#160;192)</td><td valign="top">1.06 (0.66&#8211;1.68)</td><td valign="top">0.805</td><td valign="top">1.07 (0.80&#8211;1.43)</td><td valign="top">0.615</td></tr><tr><td valign="top">Died with RD<sup>&#8224;&#8224;</sup> (n&#160;=&#160;73)</td><td valign="top"><bold>0.39 (0.14&#8211;0.88)<sup><bold>&#8225;</bold></sup></bold></td><td valign="top"><bold>0.027</bold></td><td valign="top">1.01 (0.59&#8211;1.61)</td><td valign="top">0.948</td></tr></tbody></table><table-wrap-foot><fn><p>*Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (CI) are presented for the <italic>Sl2</italic> genotype in the recessive form (i.e. <italic>Sl2/Sl2</italic> vs all other <italic>Sl</italic> genotypes) and <italic>McC<sup>b</sup></italic> genotype in the additive form (i.e. change in aOR with each additional <italic>McC<sup>b</sup></italic> allele). <italic>Sl</italic> and <italic>McC</italic> genotype were included together in a statistical model to examine their associations with malaria susceptibility. aORs displayed are adjusted for ethnicity, location of residence, sickle cell genotype, &#945;<sup>+</sup>thalassaemia genotype and ABO blood group. An interaction term between <italic>Sl</italic> genotype and &#945;<sup>+</sup>thalassaemia was included in the model. Model outputs following 2000 bootstrapped iterations are shown.</p><p><sup>&#8224;</sup>99 children (7 of whom died) were severe malaria cases whose CM status was not recorded, hence these children are included in the numbers for &#8216;All severe malaria&#8217; and &#8216;Died&#8217; but not in &#8216;with CM&#8217; or &#8216;without CM&#8217; categories.</p></fn><fn><p><sup>&#8225;</sup>Models that showed significant evidence of interaction between <italic>Sl2</italic> and &#945;<sup>+</sup>thalassaemia.</p><p><sup>&#167;</sup>CM, cerebral malaria (<italic>P. falciparum</italic> infection with a Blantyre coma score of&#160;&lt;&#160;3).</p></fn><fn><p><sup>#</sup>SMA, severe malarial anaemia (<italic>P. falciparum</italic> infection with Hb&#160;&lt;&#160;5 g/dl).</p><p><sup>&#182;</sup>34/56 cases who died with SMA also had CM.</p></fn><fn><p>**RD, respiratory distress (<italic>P. falciparum</italic> infection with abnormally deep breathing).</p><p><sup>&#8224;&#8224;</sup>56/73 cases who died with RD also had CM.</p></fn></table-wrap-foot></table-wrap>